1599-49-1 Purity
97%
If you have any other questions or need other size, please get a quote.
Specification
The third-generation fluoroquinolone antibiotic gatifloxacin demonstrates broad-spectrum antibacterial activity and specifically targets Gram-positive bacteria including penicillin-resistant Streptococcus pneumoniae. Researchers produced hydrophilic polyvinyl alcohol-sodium alginate (PVA-SA) composite nanofibers through electrospinning technology and obtained controlled drug release by actively loading gatifloxacin hydrochloride (GH).
· PVA-SA-GH Nanofiber Formulation
Preformulation of sodium alginate (SA) (2 wt %)/polyvinyl alcohol (PVA) (10 wt %) composite (2/8, 3/7 and 4/6) nanofibers was studied. Finally, the optimal ratio (3/7) was used to load gatifloxacin hydrochloride (GH) (1wt %), and it was found that smooth fibers with uniform structure were formed. The drug was loaded by active loading, and the encapsulation efficiency was 95%.
· Drug Release Behavior
The in vitro release curves showed that the drug was controlled and sustained released from the gatifloxacin-loaded PVA-SA composite nanofibers within 6 h. In addition, the thickness of the nanofibers greatly affected the initial release and drug release rate.
Gatifloxacin functions as a broad-spectrum fluoroquinolone antibiotic which demonstrates strong effectiveness against typical ocular pathogens while producing low corneal epithelial toxicity. The medication functions as a powerful antibiotic with coverage against nearly all typical ocular pathogens. This work evaluated the clinical and microbiological characteristics of eye donors and the efficacy of 0.3% gatifloxacin hydrochloride on donor corneal microbial decontamination.
· Evaluation Methods
A randomized clinical trial prospectively analyzed 513 donors and 1,026 corneas at the National Eye Bank of a tertiary care hospital during one year. The donor eyes received a treatment of 5% povidone-iodine alongside 0.4% amikacin sulfate and 0.3% gatifloxacin hydrochloride after grading.
· Evaluation Results
The cultures showed positive results in 57.6% (591/1026) of the eyes with Pseudomonas spp. being the most common organism at 53% and coagulase-negative Staphylococci at 24%. Povidone-iodine and amikacin treatment led to a significant drop in culture positivity rates with P-values of 0.002 for the right eye and 0.004 for the left eye and this reduction intensified when gatifloxacin was included (P=0.001). Gatifloxacin demonstrated effectiveness against Pseudomonas (93%), coagulase-negative Staphylococci (96.3%), Staphylococcus aureus (90.5%), enterococci, and gram-negative bacilli. Notably, multidrug-resistant Pseudomonas spp. was also susceptible to polymyxin-B. The combination of gatifloxacin hydrochloride and amikacin sulfate proves advantageous for decontaminating donor eyes.
The molecular formula of gatifloxacin hydrochloride is C19H23ClFN3O4.
Some synonyms for gatifloxacin hydrochloride are 121577-32-0, 160738-57-8, Gatifloxacin HCl, and Gatifloxacin (hydrochloride).
The molecular weight of gatifloxacin hydrochloride is 411.9 g/mol.
The IUPAC name of gatifloxacin hydrochloride is 1-cyclopropyl-6-fluoro-8-methoxy-7-(3-methylpiperazin-1-yl)-4-oxoquinoline-3-carboxylic acid;hydrochloride.
The InChI of gatifloxacin hydrochloride is InChI=1S/C19H22FN3O4.ClH/c1-10-8-22(6-5-21-10)16-14(20)7-12-15(18(16)27-2)23(11-3-4-11)9-13(17(12)24)19(25)26;/h7,9-11,21H,3-6,8H2,1-2H3,(H,25,26);1H.
The InChIKey of gatifloxacin hydrochloride is GQYBNVXJQVIRGC-UHFFFAOYSA-N.
The canonical SMILES of gatifloxacin hydrochloride is CC1CN(CCN1)C2=C(C=C3C(=C2OC)N(C=C(C3=O)C(=O)O)C4CC4)F.Cl.
The CAS number of gatifloxacin hydrochloride is 121577-32-0.
The hydrogen bond donor count of gatifloxacin hydrochloride is 3.
The hydrogen bond acceptor count of gatifloxacin hydrochloride is 8.